Dr. Reid Merryman, MD, an attending physician in the Lymphoma Program at the Dana-Farber Cancer Institute discusses Genmab and AbbVie’s preliminary data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab in patients across B-Cell lymphomas that were presented at the European Hematology Association’s (EHA) Annual Meeting 2023. Read the abstract here.
Dr. Merryman received his undergraduate degree from the University of Notre Dame and his medical degree from Harvard Medical School. He completed residency training in internal medicine at Brigham and Women’s Hospital and fellowship training in hematology and oncology at Dana-Farber/Partners Cancer Care. He is an attending physician in the Lymphoma Program at Dana-Farber Cancer Institute. His research focuses on the development of immune-based therapies for patients with lymphoma.